Trial Profile
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2007 Status changed from recruiting to completed.
- 31 May 2007 New trial record.